• Explore /
  • Poster
  • / An open-label, multicenter, adaptive, phase Ib/II study of QL1706 or QL1604 plus bevacizumab as first-line treatment in patients with advanced hepatocellular carcinoma.

An open-label, multicenter, adaptive, phase Ib/II study of QL1706 or QL1604 plus bevacizumab as first-line treatment in patients with advanced hepatocellular carcinoma.

Abstract Poster

Authors

null

Feng Bi

Department of Abdominal Oncology, West China Hospital of Sichuan University, Chengdu, China

Feng Bi , Yan-qiao Zhang , Shanzhi Gu , Yabing Guo , Zhongyuan Xu , Hao Ying , Mingxu Da , Chaoying Liu , Yaozhen Pan , Yao Huang , Zhiyu Chen , Zheng Wang , Jianbing Wu , Shangeng Weng , Yanjun Wang , Jun Zhao , Xiaokui Yu , Hui Li , Shilin Xue , Xiaoyan Kang

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2023 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary

Track

Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary

Sub Track

Hepatobiliary Cancer - Advanced/Metastatic Disease

Clinical Trial Registration Number

NCT05603039

Citation

J Clin Oncol 41, 2023 (suppl 16; abstr 4077)

DOI

10.1200/JCO.2023.41.16_suppl.4077

Abstract #

4077

Poster Bd #

398

Abstract Disclosures

Similar Posters

First Author: Ming Liu

First Author: Dale Randall Shepard

First Author: Leijuan Gan

First Author: Jaekyung Cheon